Adaptimmune Therapeutics Plc's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Adaptimmune Therapeutics Plc's ROA in the second quarter of 2025?
Adaptimmune Therapeutics Plc recorded a cumulative net loss of $-170 million during 12 months ending in the second quarter of 2025, resulting in a negative return on assets (ROA) of -58.39%.

However, within the Healthcare sector 724 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2025 from 3785 to 4343.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Total Assets Change	-48.75 %	-39.46 %	-3.92 %	-8.98 %	0.19 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-170	-70	-71	-45	-73
Return On Assets (TTM)	-58.39 %	-21.09 %	-19.79 %	-12.24 %	-19.59 %
ADAP's Total Ranking	# 4343	# 3785	# 4332	# 3568	# 3818
Total Assets (TTM) in million	171	162	563	267	334
Seq. Total Assets Change	5.95 %	-71.26 %	110.81 %	-20.16 %	25.14 %
Seq. Net Income Change	-	-	-	-	-

ADAP's 5 Years Annual ROA >> Back to ADAP Management Effectiveness >> Compare ADAP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 114
Sector	# 725
Overall	# 4288

Return On Assets Statistics
High	Average	Low
-15.09 %	-38.35 %	-79.69 %
(Sep 30 2024)		(Jun 30 2025)

Financial Statements
Adaptimmune Therapeutics Plc's Assets	$ 171 million	ADAP's Balance sheet
Adaptimmune Therapeutics Plc's Income	$ -30 million	Quarterly ADAP's Income Statement
ADAP's Income by Division		See ADAP's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-0.41 %	21.98 %	-21.7 %	9.74 %	118.15 %
Total Assets in million	583	586	480	613	559
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-71	-114	-165	-158	-130
Annual Return On Assets	-12.14 %	-19.44 %	-34.46 %	-25.78 %	-23.28 %

ADAP's 5 Years Annual ROA >> Back to ADAP Management Effectiveness >> Compare ADAP ROA to its Competitors

More Return On Assets Ratios
ADAP's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ADAP's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ADAP's Competitors
Subscribers only: Roa for Adaptimmune Therapeutics Plc's Suppliers
Subscribers only: Return On Assets for ADAP's Customers

You may also want to know
ADAP's Roi	ADAP's Inventory Turnover Ratio	ADAP's Growth Rates	ADAP's Dividend Comparisons
	ADAP's Profitability Ratios	ADAP's Asset Turnover Ratio	ADAP's Dividend Growth
ADAP's Roe	ADAP's Valuation Ratios	ADAP's Financial Strength Ratios	ADAP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector

ROA

Date modified: 2026-06-23T20:00:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.